The American Lung Association has published a new white paper, "Lung Cancer Clinical Trials: Addressing Hispanic Participation," which examines the low enrollment of Hispanic patients in lung cancer clinical trials. According to the report, while Hispanic people account for nearly 19% of the U.S. population, they represent only 6% of participants in these trials. This underrepresentation limits access to advanced treatments and restricts research aimed at improving outcomes for all lung cancer patients.
“Lung cancer clinical trials offer patients access to the newest treatments and can extend lives—but far too often, Hispanic individuals are left out,” said Harold Wimmer, President and CEO of the American Lung Association. “This white paper shines a light on a longstanding issue and offers practical, community-based solutions to ensure more patients can benefit from medical innovation.”
The research is part of the Lung Association’s Awareness, Trust and Action program. The initiative seeks to educate Hispanic communities about clinical trials and encourages discussions with healthcare providers regarding treatment options. Clinical trials are essential for advancing new lung cancer treatments. These studies are closely monitored and can test prevention methods, diagnostic tools, or new therapies. Participants receive high standards of care during these studies.
“This report is a call to action for the research community, healthcare providers, and policymakers,” Wimmer added. “By improving access and removing participation barriers, we can ensure that more people have the opportunity to benefit from the latest advancements in lung cancer treatment.”
The white paper details barriers that limit participation by Hispanic patients and proposes strategies aimed at increasing inclusion in clinical research. The American Lung Association urges stakeholders to review the complete report and collaborate on creating a more equitable clinical trial system.
Genentech provided partial support for this project.
